DA-1241 explained
| Pubchem: | 121304331 |
| Iupac Name: | 3-[4-[3-[1-(5-Ethylpyrimidin-2-yl)piperidin-4-yl]propoxy]-2,6-difluorophenyl]-5-propan-2-yl-1,2,4-oxadiazole |
| C: | 25 |
| H: | 31 |
| F: | 2 |
| N: | 5 |
| O: | 2 |
| Smiles: | CCC1=CN=C(N=C1)N1CCC(CCCOC2=CC(F)=C(C3=NOC(=N3)C(C)C)C(F)=C2)CC1 |
| Stdinchi: | 1S/C25H31F2N5O2/c1-4-17-14-28-25(29-15-17)32-9-7-18(8-10-32)6-5-11-33-19-12-20(26)22(21(27)13-19)23-30-24(16(2)3)34-31-23/h12-16,18H,4-11H2,1-3H3 |
| Stdinchikey: | XQSZLXRXPGLHLH-UHFFFAOYSA-N |
DA-1241 is an experimental GPR119 receptor agonist developed by the South Korean company Dong-A ST for non-alcoholic steatohepatitis and type 2 diabetes.[1] [2] [3] [4]
Notes and References
- Lee . Seung-Ho . Park . Hansu . Yang . Eun-Kyoung . Lee . Bo Ram . Jung . Il-Hoon . Kim . Tae-Hyoung . Goo . Moon Jung . Chae . Yuna . Kim . Mi-Kyung . GPR119 activation by DA-1241 alleviates hepatic and systemic inflammation in MASH mice through inhibition of NFκB signaling . Biomedicine & Pharmacotherapy . October 2023 . 166 . 115345 . 10.1016/j.biopha.2023.115345. 37657264 . free .
- Kim . Mi-Kyung . Cheong . Ye Hwang . Lee . Seung Ho . Kim . Tae Hyoung . Jung . Il Hoon . Chae . Yuna . Lee . Jeong-Ha . Yang . Eun Kyoung . Park . Hansu . Yang . Jae-Sung . Hong . Ki Whan . A novel GPR119 agonist DA-1241 preserves pancreatic function via the suppression of ER stress and increased PDX1 expression . Biomedicine & Pharmacotherapy . December 2021 . 144 . 112324 . 10.1016/j.biopha.2021.112324. free .
- Kim . Mi-Kyung . Lee . Dae Young . Jeong . Jiyoon . Grimm . Michael . Franey . Bridgette B. . Hompesch . Marcus . 766-P: DA-1241, a Novel GPR119 Agonist: Data on Safety, Tolerability, and Pharmacokinetics (PK) from Part 1 of a Phase 1b Multiple Ascending Dose (MAD) Study in Healthy Volunteers (HV) . Diabetes . 1 June 2021 . 70 . Supplement_1 . 10.2337/db21-766-P. 237883271 .
- Kim . Youjin . Lee . Si Woo . Wang . Hyejin . Kim . Ryeong-Hyeon . Park . Hyun Ki . Lee . Hangkyu . Kang . Eun Seok . DA-1241, a Novel GPR119 Agonist, Improves Hyperglycaemia by Inhibiting Hepatic Gluconeogenesis and Enhancing Insulin Secretion in Diabetic Mice . Diabetes & Metabolism Journal . 31 March 2022 . 46 . 2 . 337–348 . 10.4093/dmj.2021.0056. 35052026 . 8987681 . free .
